Evidence map›Paper›PMID 34831176›Full record

ArticleCells2021

Impacts of p97 on Proteome Changes in Human Cells during Coronaviral Replication.

Kai-Wen Cheng, Shan Li, Feng Wang, Nallely M Ruiz-Lopez, Nadia Houerbi, Tsui-Fen Chou

Open access · goldAbstract read
In one paragraph

Article in Cells, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. The p97 Inhibitor UPCDC-30245 Blocks Endo-Lysosomal Degradation.Pharmaceuticals (Basel, Switzerland) · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Kai-Wen ChengDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.
Shan LiDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.
Feng WangDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.
Nallely M Ruiz-LopezDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.
Nadia HouerbiDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.
Tsui-Fen ChouDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.ORCID 0000-0003-2410-2186
California Institute of Technology · US

Funding

Dysregulation of p97/VCP disease mutants in IBM and FTLD-UR01NS102279 · NINDS · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI CHOU, TSUI-FEN · 2018 to 2022
$2.8M
NINDS NIH HHS R01NS102279the Merkin Institute for Translational Research at Caltech NA
6 · The paper itself

Abstract

Human coronavirus (HCoV) similar to other viruses rely on host cell machinery for both replication and to spread. The p97/VCP ATPase is associated with diverse pathways that may favor HCoV replication. In this study, we assessed the role of p97 and associated host responses in human lung cell line H1299 after HCoV-229E or HCoV-OC43 infection. Inhibition of p97 function by small molecule inhibitors shows antiviral activity, particularly at early stages of the virus life cycle, during virus uncoating and viral RNA replication. Importantly, p97 activity inhibition protects human cells against HCoV-induced cytopathic effects. The p97 knockdown also inhibits viral production in infected cells. Unbiased quantitative proteomics analyses reveal that HCoV-OC43 infection resulted in proteome changes enriched in cellular senescence and DNA repair during virus replication. Further analysis of protein changes between infected cells with control and p97 shRNA identifies cell cycle pathways for both HCoV-229E and HCoV-OC43 infection. Together, our data indicate a role for the essential host protein p97 in supporting HCoV replication, suggesting that p97 is a therapeutic target to treat HCoV infection.

Indexed as

Antiviral AgentsCell CycleCell LineCoronavirus 229E, HumanCoronavirus OC43, HumanCytopathogenic Effect, ViralHumansProteomeRNA, Small InterferingRNA, ViralValosin Containing ProteinVirus ReplicationVirus UncoatingAntiviral AgentsProteomeRNA, Small InterferingRNA, ViralValosin Containing ProteinVCP protein, humanATPasecoronavirusinhibitorp97proteomics

Identifiers

PMID34831176
PMCPMC8616207
OpenAlexW3208641224

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.